Rheumatoid Arthritis (Vaccine Development)

Phase II Data Presented on Rheumatoid Arthritis Vaccine

Published in Vaccine Weekly, November 29th, 1999

The Immune Response Corporation announced that data from a Phase IIb clinical trial of the company's proprietary immune-based therapy for rheumatoid arthritis (IR501 and IR703 Therapeutic Vaccines) were presented by Dr. Alan Matsumoto of Johns Hopkins University, Baltimore, Maryland, at the American College of Rheumatology (ACR) Annual Meeting in Boston, Massachusetts.

The immune-based investigational therapy appeared safe and well tolerated, and a statistically significant (P< 0.05) percentage of patients with improvement in their disease condition was observed after the third injection of IR501 Therapeutic Vaccine using the ACR 20 criteria for improvement. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry